Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase Ib/II Study of the Safety, Tolerability and Efficacy of G207, a Genetically Engineered Herpes Simplex Type-1 Virus, Administered Intracerebrally to Patients With Recurrent Malignant Glioma

NCT00028158 is registered in ClinicalTrials.gov with MediGene as lead sponsor.

NCT NCT00028158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00028158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase Ib/II Study of the Safety, Tolerability and Efficacy of G207, a Genetically Engineered Herpes Simplex Type-1 Virus, Administered Intracerebrally to Patients With Recurrent Malignant Glioma
Lead sponsor
MediGene
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2001
Completion date
October 31, 2003
Enrollment
65
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, glioblastoma, glioma